Logo

OGeS Raises Equity Funding for Dx Development

Feb 05, 2007
NEW YORK (GenomeWeb News) - Oxford Genome Sciences today said it has received an equity placement from three investors, including previous investors South East Growth Fund and Oxford Capital Partners, and first-time investor Catapult Growth Fund.
 
A company spokesperson declined to disclose the amount of the financing.
 
OGeS develops disease-related proteins for use in cancer diagnostics and therapeutics.
 
The company is focusing on antibody therapies that are accompanied by a diagnostic to help guide treatment.

Breaking News
The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.